TMCI TREACE MED CONCEPTS INC

Treace Announces Participation in the Morgan Stanley 20th Annual Global Healthcare Conference

Treace Announces Participation in the Morgan Stanley 20th Annual Global Healthcare Conference

PONTE VEDRA, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, beginning at approximately 8:35 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit .

Contacts:

Treace Medical Concepts

Mark L. Hair

Chief Financial Officer



(904) 373-5940

Investors:

Gilmartin Group

Lynn Lewis or Vivian Cervantes



EN
24/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TREACE MED CONCEPTS INC

 PRESS RELEASE

Treace Medical Concepts Reports First Quarter 2025 Financial Results

Treace Medical Concepts Reports First Quarter 2025 Financial Results PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship  and  Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2...

 PRESS RELEASE

Treace to Report First Quarter 2025 Financial Results on May 8, 2025

Treace to Report First Quarter 2025 Financial Results on May 8, 2025 PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm...

 PRESS RELEASE

Treace Announces Upcoming Board Chair Transition

Treace Announces Upcoming Board Chair Transition PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace w...

 PRESS RELEASE

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty...

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship  and  Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of ...

 PRESS RELEASE

Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific ...

Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference Expands market-leading position with new best-in-class bunion technologies PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Confer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch